Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DXC006 in Advanced Solid Tumors and Hematologic Malignancies
NCT06224855Phase 1Recruiting
- Sponsor
- Hangzhou DAC Biotech
- Start
- Jan 2024
- Primary completion
- Jun 2027
- Modality
- Small Molecules, Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of DXC-006 in solid tumor, hematologic malignancy, small cell lung cancer (SCLC) and 2 more, sponsored by Hangzhou DAC Biotech. Primary endpoints: Dose Limiting Toxicities at 28 days and Adverse Events at 1 year. Started Jan 2024; status: recruiting.
02
Drugs
DXC-006
03
Conditions
solid tumorhematologic malignancysmall cell lung cancer (SCLC)multiple myeloma (MM)neuroblastoma
Beyond the preview
Go deeper on NCT06224855.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06224855.